

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number
WO 2022/184824 A3

(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 16/30 (2006.01)
A61K 35/768 (2015.01) C12N 5/0783 (2010.01)
A61P 35/00 (2006.01) A61K 39/00 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/EP2022/055394

(22) International Filing Date:

03 March 2022 (03.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21160732.0 04 March 2021 (04.03.2021) EP

(71) Applicant: **DEUTSCHES KREBS-
FORSCHUNGSZENTRUM STIFTUNG DES ÖF-
FENTLICHEN RECHTS** [DE/DE]; IM NEUEN-
HEIMER FELD 280, 69120 HEIDELBERG (DE).

(72) Inventors: **HALAMA, Niels**; Deutsches Krebs-
forschungszentrum, Stiftung des öffentlichen Rechts, In-
novaion Management, T010, Im Neuenheimer Feld 280,
69120 Heidelberg (DE). **JÄGER, Dirk**; Deutsches Krebs-
forschungszentrum, Stiftung des öffentlichen Rechts, In-

novaion Management, T010, Im Neuenheimer Feld 280,
69120 Heidelberg (DE). **SCHMIDT, Patrick**; Deutsches
Krebsforschungszentrum, Stiftung des öffentlichen Rechts,
Innovaion Management, T010, Im Neuenheimer Feld 280,
69120 Heidelberg (DE).

(74) Agent: **SCHÜSSLER, Andrea**; TRUDERINGER
STRASSE 246, 81825 MÜNCHEN (DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1




Fig. 7

(57) Abstract: The present invention relates to compositions, methods, uses and kits for combination therapies involving immunotherapies, such as adaptive cell therapy, e.g., T cell therapy, and an oncolytic virus (particularly parvovirus H-1), for treating subjects with cancer. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the cancer is a solid tumor or a hematological malignancy.

WO 2022/184824 A3

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

24 November 2022 (24.11.2022)